Anahita Arian1, Sayyed Gholamreza Mortazavi Moghadam2, Toba Kazemi1, Morteza Hajihosseini1. 1. Birjand Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran. 2. Department of Internal Medicine, Pulmonary Division, Atherosclerosis and Coronary Artery Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Abstract
OBJECTIVE: Pulmonary hypertension is a serious complication in patients suffering from chronic obstructive pulmonary disease (COPD). The aim of this study is to investigate the effects of atorvastatin in reducing pulmonary arterial pressure in COPD patients. METHODS: This double-blind, randomized trial was conducted on 42 known cases of COPD with systolic pulmonary arterial pressure of more than 25 mmHg. The patients were randomly assigned into two groups, 21 patients with atorvastatin treatment (40 mg/daily for 6 months) and 21 patients without receiving atorvastatin. All the patients participated voluntarily and provided written informed consent. The trial was registered in the Iranian Registry of Clinical Trials. Pulmonary pressure was also anticipated by Doppler echocardiography with peak pressure gradient of tricuspid regurgitation. Both groups were tested with echocardiography to measure systolic pulmonary pressure at baseline and posttreatment. Statistical analysis includes Chi-square, Student's t-test, and Wilcoxon test. P < 0.05 was considered statistically significant. FINDINGS: The mean age was 65.8 ± 11.5 years for atorvastatingroup and 63.7 ± 7.6 years for control group (P = 0.45). Baseline and posttreatment mean systolic pulmonary artery pressure (PAP) levels in the atorvastatin group were 48.9 ± 3.3 and 38.4 ± 1.9 mmHg, respectively (P = 0.007). In the control group, mean systolic PAP levels at baseline and 6 months later were 45.6 ± 3.1 and 38.9 ± 2.4 mmHg, respectively (P = 0.073). The patients treated with atorvastatin showed significant decrease in total cholesterol (P = 0.001) and low-density lipoprotein cholesterol (P = 0.008). CONCLUSION: A 40 mg dose of atorvastatin daily for 6 months may have beneficial effects in reducing PAP in patients with COPD. Further studies are necessary to find long-term effects of statins in COPD patients.
RCT Entities:
OBJECTIVE:Pulmonary hypertension is a serious complication in patients suffering from chronic obstructive pulmonary disease (COPD). The aim of this study is to investigate the effects of atorvastatin in reducing pulmonary arterial pressure in COPDpatients. METHODS: This double-blind, randomized trial was conducted on 42 known cases of COPD with systolic pulmonary arterial pressure of more than 25 mmHg. The patients were randomly assigned into two groups, 21 patients with atorvastatin treatment (40 mg/daily for 6 months) and 21 patients without receiving atorvastatin. All the patients participated voluntarily and provided written informed consent. The trial was registered in the Iranian Registry of Clinical Trials. Pulmonary pressure was also anticipated by Doppler echocardiography with peak pressure gradient of tricuspid regurgitation. Both groups were tested with echocardiography to measure systolic pulmonary pressure at baseline and posttreatment. Statistical analysis includes Chi-square, Student's t-test, and Wilcoxon test. P < 0.05 was considered statistically significant. FINDINGS: The mean age was 65.8 ± 11.5 years for atorvastatin group and 63.7 ± 7.6 years for control group (P = 0.45). Baseline and posttreatment mean systolic pulmonary artery pressure (PAP) levels in the atorvastatin group were 48.9 ± 3.3 and 38.4 ± 1.9 mmHg, respectively (P = 0.007). In the control group, mean systolic PAP levels at baseline and 6 months later were 45.6 ± 3.1 and 38.9 ± 2.4 mmHg, respectively (P = 0.073). The patients treated with atorvastatin showed significant decrease in total cholesterol (P = 0.001) and low-density lipoprotein cholesterol (P = 0.008). CONCLUSION: A 40 mg dose of atorvastatin daily for 6 months may have beneficial effects in reducing PAP in patients with COPD. Further studies are necessary to find long-term effects of statins in COPDpatients.
Authors: Vallerie V McLaughlin; Kenneth W Presberg; Ramona L Doyle; Steven H Abman; Douglas C McCrory; Terry Fortin; Gregory Ahearn Journal: Chest Date: 2004-07 Impact factor: 9.410
Authors: Martin R Wilkins; Omar Ali; William Bradlow; John Wharton; Anne Taegtmeyer; Christopher J Rhodes; Hossein A Ghofrani; Luke Howard; Petros Nihoyannopoulos; Raad H Mohiaddin; J Simon R Gibbs Journal: Am J Respir Crit Care Med Date: 2010-05-15 Impact factor: 21.405
Authors: Steven M Kawut; Emilia Bagiella; David J Lederer; Daichi Shimbo; Evelyn M Horn; Kari E Roberts; Nicholas S Hill; R Graham Barr; Erika B Rosenzweig; Wendy Post; Russell P Tracy; Harold I Palevsky; Paul M Hassoun; Reda E Girgis Journal: Circulation Date: 2011-05-18 Impact factor: 29.690
Authors: Michael McGoon; David Gutterman; Virginia Steen; Robin Barst; Douglas C McCrory; Terry A Fortin; James E Loyd Journal: Chest Date: 2004-07 Impact factor: 9.410